Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus radiotherapy in advanced metastatic non-squamous non-small cell lung cancer
2015-005741-31Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Primary endpoint: Overall response rate (ORR). Started Jul 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005741-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005741-31.